Unbuzzd Wellness Inc., licensee of Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM), will host an investor webinar on September 16, 2025, at 1:30 p.m. PT to discuss the Reg D 506(c) investment opportunity for its unbuzzd(TM) beverage. The event will feature company leadership including CEO John Duffy, Advisor Jason Sawyer, Medical Director Dr. Eric Hoskins, and Board Co-Chair Gerry David presenting clinical data and sales acceleration strategies.
The webinar's focus on unbuzzd(TM), a beverage scientifically proven to accelerate alcohol metabolism, restore mental clarity, and reduce hangover symptoms, represents significant implications for both consumer health and investment markets. This presentation comes at a time when alcohol-related products face increasing scrutiny regarding efficacy and scientific validation, making transparent clinical data disclosure crucial for market credibility.
Quantum BioPharma's relationship with Unbuzzd Wellness includes substantial financial arrangements that underscore the product's potential market value. The company retains 20.11% ownership of Unbuzzd Wellness as of March 31, 2025, and receives royalty payments of 7% of sales until payments total $250 million, after which the royalty drops to 3% in perpetuity. These terms indicate long-term revenue potential and confidence in the product's commercial viability.
The investment opportunity presentation aligns with Quantum BioPharma's broader focus on neurodegenerative and metabolic disorders through its subsidiary Lucid Psycheceuticals Inc., which develops Lucid-MS for multiple sclerosis treatment. The company maintains pharmaceutical rights to develop similar products for medical uses, suggesting potential expansion into therapeutic applications beyond consumer wellness products.
For investors, the webinar provides access to detailed clinical data and business strategies that could influence investment decisions in the growing wellness beverage market. The event's timing and content may impact market perception of both Unbuzzd Wellness and Quantum BioPharma, particularly given the latter's NASDAQ and CSE listings. Additional information about Quantum BioPharma is available in the company's newsroom at https://ibn.fm/QNTM.
The broader implications extend to consumer health markets where scientifically validated alcohol metabolism products could address public health concerns related to alcohol consumption. As regulatory scrutiny increases around health claims in beverages, transparent clinical data presentation becomes increasingly important for market acceptance and regulatory compliance.
